Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: VNRX
Market: NYSE
Sector: Pharma & Biotech
VolitionRx

VolitionRx

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

VolitionRx

www.volitionrx.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in VolitionRx


VolitionRx Snapshot

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

 

 

Conditions

Colorectal Cancer

Volition’s initial Nu.Q™ products are focusing on colorectal cancer. Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide.

• The Nu.Q™ Colorectal Cancer Screening Triage Test has demonstrated the potential to reduce colonoscopies by up to 24.5% while maintaining almost 95% detection of colorectal cancer. This product is CE Marked and is available for use in the EU Markets.

Products in development

• Interim results of a panel of 4 Nu.Q™ assays detected 81% of colorectal cancers at 78% specificity in a cohort of 4800 symptomatic patients.

• A panel of 4 normalised Nu.Q™ assays detected 67% of high risk adenomas at 80% specificity in a cohort of 530 symptomatic patients.

Pancreatic Cancer

There is a clear medical need for a reliable, simple, and accurate diagnostic test for pancreatic cancer. Currently, emergency presentation is the most common route to diagnosis, and only 21% of patients survive for more than a year.

•  A panel of 4 Nu.Q™ assays plus CA19-9 in a pilot study of 59 patients detected 92% of pancreatic cancers at 100% specificity

• Interim results of a panel of 2 Nu.Q™ assays plus CEA detected 95% of pancreatic cancers at 84% specificity.

Lung Cancer

Lung cancer is the most common cancer worldwide. Only 10% of lung cancer patients will survive for five years or more. Current screening methods for lung cancer are widely regarded as too inaccurate and expensive for widespread use.

• A panel of 4 Nu.Q™ assays in a pilot study of 73 patients detected 93% of lung cancers at 91% specificity.

Ongoing clinical trials

Technology

Cancer leads to irregular levels of uniquely structured nucleosomes in the blood. A nucleosome is a section of DNA wrapped around a core of proteins. Through a simple test, with less than a drop of blood, we are able to detect those unique nucleosomes; and by measuring and analysing them, our Nu.Q™ tests can establish whether cancer is present is present in the patient.

Volition Nu.QTM ELISA

Volition has developed five patentprotected families of Nu.QTM sandwich ELISA assays, each of which captures intact nucleosomes and labels (identifies) a specific structural feature:
• Nu.QTM - V histone variants
• Nu.QTM - M histone modifications
• Nu.QTM - X specific DNA modifications
• Nu.QTM - A nucleosome-protein adducts
• Nu.QTM - T total nucleosomes

 

EXECUTIVE TEAM

Cameron Reynolds MBA - President & Chief Executive Officer

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.
Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Jake Micallef PhD MBA - Chief Scientific Officer

Jake is an experienced scientist with expertise in research and development and in the management of early stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake received his BSc in Biology and Chemistry, and his PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology from St Thomas’ Hospital Medical School, and his MBA from Imperial College Management School.

Gaetan Michel PhD - Chief Executive Officer of Belgian Volition SPRL

Gaetan has over 10 years of experience in production management. Following the completion of his PhD in 2002, Gaetan joined AAT (Advanced Array Technology), a University of Namur spin-off company as project manager in proteomics. AAT later became EAT (Eppendorf Array Technology), part of the German Eppendorf Biotech company, where Gaetan became production manager and was involved in establishing production processes and equipment. From 2007 to 2010 he worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health.

Jason Terrell MD - Chief Medical Officer & Chief Executive Officer of Volition America, Inc.

Jason has expertise in clinical medicine and in laboratory diagnostics. He was educated at Hardin-Simmon University (Biochemistry) where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his Doctor of Medicine from the University of Texas Medical School at Houston and affiliate MD Anderson Cancer Center.

Jason has a strong grounding in both medicine and more specifically in diagnostics and product commercialization.


Louise Day - Chief Marketing and Communications Officer

Louise brings more than 20 years of marketing, sales and leadership experience to her role at Volition. Since 2011, she has served as Director and Owner of Aculd Ltd, a strategic marketing consultancy specializing in healthcare. Formerly Louise worked in various roles at Reckitt Benckiser including some overseas posts in Paris and New York. She holds a Bachelor of Arts in Business Studies from Sheffield Hallam University.

David Vanston MBA FCCA - Chief Financial Officer

David has 20 years of financial management experience. Prior to Volition and Octo Telematics, David held positions as Vice President of Excorp Medical, Inc., an early-stage company, Chief Financial Officer for GrowHow Ltd and Vice President Europe, Finance for Monster Worldwide, Inc. David managed and oversaw the accounting, finance, tax, treasury, financial planning and analysis of the business.
David is a certified chartered accountant and holds an MBA from Warwick Business School.

Rod Rootsaert LLB - Corporate Secretary

Rod is an experienced legal and corporate secretary with over ten years’ experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a Bachelor of Laws degree from the University of Western Australia.

Jasmine Kway PhD - Vice President, Asia

Jasmine has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes. As a thought leade in technology management and commercialization, she has worked with numerous health and regulatory bodies across Asia and has successfully comercialised technologies and expanded companies into the Asian markets.
Jasmine has a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.

 

BOARD OF DIRECTORS

Cameron Reynolds - President & Group Chief Executive Officer

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Dr. Martin C Faulkes - Chairman

Dr. Martin Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States.

From 1979 to 1984, Dr. Faulkes was the Founder, President and CEO for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business; namely sales, finance, recruitment,staff management and project control. He then became Managing Director of System Programming Ltd., a company that provides computer programming for systems in business like airlines, utility companies, banks, and insurance, from 1985 to 1987, where he was responsible for all aspects of the business. Dr. Faulkes founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a director from 1987 to 1998, responsible for controlling the company financially.

From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the Founder and Sole Benefactor of the Dill Faulkes Educational Trust, a UK registered charity, where he is Chairman. He also sits on the Board of the Cambridge 800th Anniversary Campaign in the UK.

Dr. Alan Colman - Non-Executive Director

Alan Colman obtained a BA degree in Biochemistry in Oxford (1971) and a PhD under John Gurdon, a pioneer of the field of nuclear transfer, at the Laboratory of Molecular Biology in Cambridge, UK (1974). After a series of academic appointments in Oxford and Warwick Universities, he became Professor of Biochemistry in the University of Birmingham, UK from 1987-1992. The focus then of his academic career was the area of eucaryotic protein secretion, with a particular emphasis on the use of frog oocytes and eggs as in vivo test tubes.

From 1987 until March 2002, he was research director of the company PPL Therapeutics in Edinburgh, UK. This company specialized in the production of transgenic livestock that produced human therapeutic proteins in their milk.  PPL attracted considerable media attention because of their use of somatic cell nuclear transfer in a collaboration with the neighboring Roslin Institute. This work led to Dolly, the world’s first sheep cloned from an adult somatic cell (1996).

From 2002-2007, he was CSO and then CEO for the Singaporean human embryonic stem cell company, ES Cell International.  Following this, he served as Executive Director of the Singapore Stem Cell Consortium and a Principal Investigator at the Singapore A*STAR Institute of Medical Biology (2006-2013) whilst concurrently Professor of Regenerative Medicine at King’s College, London, UK (2008-2009). His main research interest during these appointments was the development of human disease models using induced pluripotent stem cells.

In addition to his roles with Volition (2011- present ), Dr. Alan Colman acts as senior scientific advisor to Genea Biocells in San Diego, USA, and is a Visiting Scholar at the Harvard University Department of Stem Cell and Regenerative Biology (2014- present).

Guy Innes - Non-Executive Director

Guy Archibald Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales.

Mr. Innes has extensive experience in financing and managing technology companies, which he gained from serving as a non-executive director on the board of companies such as ProBio Inc. from 2000 to 2006, Magellan Copper & Gold Plc. from 2007 to 2010, and Carbon Mining Plc. from 2007 to 2010.

Prior to holding these directorships, Mr. Innes had a long career in banking and private equity, including advisory roles with Baring Brothers & Co. Limited in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers & acquisitions, but also IPOs and capital raising; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Quartz Capital Partners Limited from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions.

Mr. Innes was educated at the University of Bristol (BSc Geography), and is a Member of the Institute of Chartered Accountants in England and Wales.

Dr. Edward Futcher - Non-Executive Director

Dr. Futcher holds a B.Sc. in Physics and a Ph.D. in Physics from the University of London and has extensive experience in engineering and management in high technology companies.  Since 1997, Dr. Futcher has held non-executive directorships at a variety of private companies. He co-founded Azima, Inc. in 2003, a company that provides advanced machine diagnosis to large industrial facilities and, from 2003 to 2008, served as its Vice President of Engineering. Prior to that, from 1997 to 2003, Dr. Futcher served as Vice President of Technology at interWAVE Communications International Ltd., a company providing GSM and CDMA cellular infrastructure equipment, and from 1997 to 1999 he also served as interWAVE's Vice President of Engineering.  From 1994 to 1997, Dr. Futcher was Director of Engineering at Tellabs, Inc.

Dr. Habib Skaff - Non-Executive Director

Dr. Habib Skaff is a synthetic chemist specializing in the area of nanotechnology, as well as founder and CEO of Intezyne Technologies.

Dr. Skaff received a Ph.D. in Polymer Science and Engineering from the University of Massachusetts. His doctoral studies involved the design of organic and polymeric ligands for the encapsulation of semiconductor nanoparticles and modification of the physical, optical, electronic, and assembly properties of the nanoparticles. He possesses a M.S. in Polymer Science and Engineering from the University of Massachusetts and a B.S. degree in Materials Science and Engineering (Honors) from the University of Florida. He has co-authored 11 peer-reviewed scientific papers and is a co-inventor on 18 pending or issued patents in the fields of chemistry, nanotechnology, and biotechnology.

Dr. Skaff co-founded Intezyne Technologies and serves as the company's Chief Executive Officer, President, and Chairman of the Board of Directors. Dr. Skaff also held the position of President and is currently the Chairman of Skaff Corporation of America (Tampa, Florida). Dr. Skaff serves as a member of the Florida High Tech Corridor Council and as an advisor for the USF Center for Entrepreneurship.

 

For more information on the management team, please click here

BELGIUM
Belgian Volition SPRL
22 Rue Phocas Lejeune
Parc Scientifique Crealys
5032 Isnes

LONDON
Volition Diagnostics UK Ltd
93-95 Gloucester Place
London
W1U 6JQ

NEW YORK
VolitionRx
One Rockefeller Plaza
10th Floor
New York, NY 10020

SINGAPORE
VolitionRx
1 Scotts Road
#24-05 Shaw Centre
Singapore

Investor Relations

VolitionRx
Scott Powell
T: (646) 650-1351
[email protected]
Investor Relations

Edison Advisors
Tirth Patel
T: (646) 653-7035
[email protected]


Edison Advisors
Rachel Carroll
T: +44 (0) 20 3077 5711
[email protected]


Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
[email protected]
www.vstocktransfer.com

Auditor
Sadler Gibb & Associates, LLC

2455 East Parleys Way
Suite 320
Salt Lake City, UT 84109

Legal Counsel
Stradling Yocca Carlson & Rauth, P.C.

660 Newport Center Drive
Suite 1600
Newport Beach, CA 92660

VolitionRx Timeline

Newswire
April 11 2017

Market Reports Including VNRX

VIEW ALL

Videos

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use